Introduction
The molecular basis of human malignant melanoma progression has remained largely unknown despite the fact that the worldwide incidence of melanoma is increasing more than any other neoplastic disease (Kopf et al., 1995) . The molecular changes associated with the transition of melanoma cells from radial growth phase (RGP) to vertical growth phase (VGP, metastatic phenotype) are not well defined. Since the production of metastases depends on the completion of a multistep process involving the survival and growth of a unique subpopulation of cells
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with metastatic properties (Fidler, 1990 ), more information is clearly needed regarding genetic changes underlying melanoma tumorigenesis and progression to provide insights into the development of this cancer.
There has, however, been some progress. Of particular relevance to this paper are recent results with the c-KIT receptor in melanoma. Expression of the tyrosine kinase receptor encoded by the c-KIT proto-oncogene progressively decreases during local tumor growth and invasion of human melanomas (Lassam and Bickford, 1992; Natali et al., 1992; Zakut et al., 1993) . The proto-oncogene c-KIT encodes a transmembrane tyrosine-protein kinase receptor related to the PDGF/CSF-1 (c-fms) receptor subfamily (Yarden et al., 1987) . c-KIT has been found to play a pivotal role in the normal growth and differentiation of embryonic melanoblasts. In mice, c-KIT has been mapped to the dominant white spotting (w) locus (Chabot et al., 1988; Geissler et al., 1988) , whose ligand is the product of the sl locus (Steel) (Zsebo et al., 1990) which encodes the stem cell factor, SCF (also known as KITligand, KL, steel factor or mast cell growth factor, MCF). Mutations in the (w) locus or (sl) locus (Nocka et al., 1989 Reith et al., 1990; Tan et al., 1990; Brannan et al., 1991; Flanagan et al., 1991) , or injection of neutralizing anti-KIT antibodies into pregnant mice (Nishikawa et al., 1991) results in the piebald phenotype, characterized by white spotting of the fur and attributed to a local reduction in the number of cutaneous melanocytes. Mutations in the c-KIT receptor also have been identified in human piebald patients (Fleishman et al., 1991; Gibel and Spritz, 1991; Fleischman, 1992) , suggesting that normal function of c-KIT is required for human melanocyte development.
These observations raise the question as to whether malignant transformation of melanocytes may be associated with changes in the expression of the c-KIT receptor. Indeed, several recent studies have demonstrated that the progression of human cutaneous melanoma is associated with loss of expression of the c-KIT proto-oncogene. About 70% of metastatic lesions and human melanoma cell lines do not express detectable levels of the c-KIT receptor (Lassam and Bickford, 1992; Natali et al., 1992; Zakut et al., 1993) . To provide direct evidence that c-KIT plays a role in metastasis of human melanoma, we transfected the c-KIT gene into c-KIT-negative, highly metastatic human melanoma cells and subsequently analyzed their tumorigenic and metastatic potential in nude mice (Huang et al., 1996) . Enforced c-KIT expression significantly inhibited tumor growth and metastasis. Exposure of c-KIT-positive melanoma cells in vitro and in vivo to SCF, the ligand for c-KIT, triggered apoptosis of these cells but not of normal melanocytes. These results suggest that loss of c-KIT receptor may allow malignant melanoma cells to escape SCF/c-KIT-mediated apoptosis, thus contributing to tumor growth and eventually metastasis (Huang et al., 1996) . The mechanism(s) for the loss of c-KIT gene expression during melanoma progression are unknown. The promoter of the c-KIT gene has been cloned and sequenced (Yamamoto et al., 1993) . The human c-KIT promoter region lacks a typical 'TATA box' but has a relatively high GϩC content and strikingly, three putative AP-2-binding elements. These observations, coupled with our previous finding that highly metastatic human melanoma cells do not express the AP-2 transcription factor (Bar-Eli, 1997), led us to hypothesize that AP-2 may regulate c-KIT gene expression in human melanoma cells.
AP-2, a 52 kDa protein, was first purified from HeLa cells. Partial peptide sequences led to the isolation of the cDNA from a HeLa cell library (Williams et al., 1988) , and the gene was mapped to a region on the short arm of chromosome 6 near the HLA locus (Gaynor et al., 1991; Mitchell et al., 1991) . The AP-2 protein binds to a consensus palindromic core recognition element with the sequence 5Ј-GCCNNNGGC-3Ј (Williams et al., 1988) . Functional AP-2-binding sites have been identified in the enhancer regions of viral genes such as simian virus 40 (SV40) (Mitchell et al., 1987) , human T-cell leukemia virus type I (Nyborg and Dynan, 1990) , and cellular genes such as murine major histocompatibility complex (H-2K b ), human metallothionein-IIa (huMTIIa), human proenkephalin, human keratin K14 genes, c-erbB-2, plasminogen activator inhibitor type I (PAI-1) and insulinlike growth factor binding protein-5 (Lee et al., 1981; Haslinger and Karin, 1985; Hyman et al., 1989; Leask et al., 1991; Descheemaeker et al., 1992; Bosher et al., 1995; Duan and Clemmons, 1995) . The DNA-binding domain is located within the C-terminal half of the 52 kDa protein and consists of two putative amphipathic α helices separated by an 82 amino acid intervening span that is both necessary and sufficient for homodimer formation (Williams and Tjian, 1991 ). An alternatively spliced AP-2 protein, AP-2B, that differs in its C-terminus and acts as dominant-negative to AP-2 has recently been cloned (Buettner et al., 1993) .
AP-2 activity is regulated through a number of different signal transduction pathways. Phorbol esters and signals that enhance c-AMP levels induce AP-2 activity independently of protein synthesis, whereas retinoic acid treatment of teratocarcinoma cell lines results in a transient induction of AP-2 mRNA levels on a transcriptional level (Luscher et al., 1989; Buettner et al., 1993) .
AP-2 is involved in mediating programmed gene expression both during embryonic morphogenesis and adult cell differentiation. Using in situ hybridization, a restricted spatial and temporal expression pattern has been observed during murine embryogenesis. In particular, regulated AP-2 expression was observed in neural crest-derived cell lineages (from which melanocytes are derived) and in facial and limb bud mesenchyme (Mitchell et al., 1991) . Two recent reports of AP-2 null mutant mice have demonstrated that AP-2 is important for development of the cranial region and for midline fusions. The AP-2 null mice died at birth (Schorle et al., 1996; Zhang et al., 1996) .
In this study, we provide the first evidence that (i) there is a direct correlation between AP-2 and c-KIT expression in human melanoma cells; (ii) transfection of highly Luciferase activity driven by the c-KIT promoter in human melanoma cell lines. 2 μg of c-KIT luciferase reporter gene construct pKluc and 0.05 μg of pB-Actin-RL (Renilla) plasmid were cotransfected into 2ϫ10 5 melanoma cells, and incubated for 60 h at 37°C. Firefly and Renilla luciferase activities were quantified using the Dual-Luciferase Reporter Assay System. Luciferase activity was compared with c-KIT-negative A375SM cells which were given the reference value of 1. Higher luciferase activity was observed in the two c-KIT-positive cell lines, Mel-501 and Mel-888, than in the c-KITnegative cell line, WM2664. The standard deviation bars represent replicates within the assay. This experiment is a representative of three performed.
metastatic cells (c-KIT negative, AP-2 negative) with the AP-2 gene resulted in induction of c-KIT mRNA and protein; and (iii) re-expression of AP-2 in highly metastatic melanoma cells inhibited their tumor growth and metastatic potential in nude mice, possibly through transactivation of c-KIT. Our results add weight to the hypothesis that loss of AP-2 expression is a crucial event in the development of malignant melanoma, especially since other genes involved in the progression of human melanoma such as MCAM/ MUC18, E-cadherin, MMP-2 and p21/WAF-1 are also regulated by AP-2.
Results
Direct correlation between c-KIT and AP-2 expression in human melanoma cell lines The mechanism(s) for lack of expression of c-KIT in metastatic melanoma cells is unknown. In an effort to determine the molecular basis for c-KIT's lack of expression in highly metastatic melanoma cells, we found that the c-KIT gene and its promoter in c-KITnegative melanoma cells had no abnormalities (deletions, rearrangements or mutations) that can account for the lack of c-KIT expression (Huang et al., 1996; Bar-Eli, 1997 ; data not shown). These observations suggest that c-KIT expression might be regulated at the transcriptional level. To test this hypothesis, we subcloned the promoter of the c-KIT gene (-1215 to ϩ1) (Yamamoto et al., 1993) in front of the luciferase reporter gene. Using the Dual-Luciferase Reporter System, we analyzed the luciferase activity driven by the c-KIT promoter in c-KIT-positive and c-KIT-negative melanoma cell lines. As shown in Figure 1 , c-KIT-luciferase activity was higher in the human melanoma cell lines Mel-888 and Mel-501 (both express high levels of c-KIT mRNA) (Zakut et al., 1993) , as compared with the activity in c-KIT-negative A375SM cells which was given the reference value of 1. We observed low luciferase activity (Buettner et al., 1993) . The same filter was hybridized with GAPDH to verify the integrity and the amount of RNA loaded in each lane.
in the WM-2664 cell line which does not express c-KIT mRNA and protein (Gutman et al., 1994) . These results suggest that c-KIT expression is regulated at the transcriptional level in these melanoma cells.
The 1.2 kb c-KIT promoter lacks TATA or CCAAT boxes, is highly GϩC rich, and contains binding sites for SP-1, myb, GATA-1 and three putative AP-2 sites (Yamamoto et al., 1993) . Deletion of the proximal 185 bp of the promoter abolished the transcription of c-KIT in HEL cells, suggesting that only the proximal 185 bp of the promoter are necessary and sufficient for c-KIT expression (Yamamoto et al., 1993) . As we closely examined the proximal 185 bp promoter region, two AP-2 binding sites were identified within this region with a total of three putative AP-2 binding motifs within the 1.2 kb c-KIT promoter ( Figure 3C ). The presence of two AP-2-binding sites within the essential region of c-KIT promoter suggested that AP-2 might regulate expression of the c-KIT gene. Indeed, during mouse development, AP-2 and c-KIT are co-expressed in several tissues including hindbrain, kidney and heart, and in neural crest-derived lineages from which melanocytes originate (Orr-Urtreger et al., 1990; Mitchell et al., 1991) . These observations prompted us to analyze whether the progression of human melanoma is associated with changes in the expression of the AP-2 transcription factor via regulation of the c-KIT gene.
To study whether AP-2 plays a role in the regulation of c-KIT expression in human melanoma cells, we first examined the status of AP-2 in a panel of human melanoma cell lines exhibiting different metastatic capabilities in nude mice (Luca et al., 1995; Bar-Eli, 1997; Xie et al., 1997) . Figure 2 demonstrates that expression of AP-2, correlated with the expression of c-KIT and the metastatic potential of human melanoma cells i.e. the non/low metastatic melanoma cell lines in nude mice such as MeWo, Mel-501, Mel-888, SB-2 and SB-3, expressed high levels of c-KIT and the two AP-2 transcripts. In contrast, the cell lines derived from metastatic lesions and also metastatic in nude mice (Luca et al., 1995) A375P, A375SM and WM-2664 were c-KIT negative and were also either negative for AP-2 (A375SM), or expressed negligible amounts of AP-2 mRNA (A375P, WM-2664). Expression of AP-2 in the nonmetastatic SB-2 cells and lack of expression of AP-2 in the highly metastatic A375SM cells was confirmed by Western blot analysis (Bar-Eli, 1997; see Figures 6 and 7) .
Transactivation of c-KIT promoter by AP-2A and repression by the dominant-negative AP-2B gene To assess the effect of AP-2 on c-KIT transcription, the c-KIT promoter-luciferase construct, pKLuc, was co-transfected into A375SM cells with increasing concentrations of an expression vector encoding for wild-type AP-2 (AP-2A, pSG5-AP-2) or with the control vector lacking AP-2A (pSG5). Using the β-actin-Renilla luciferase plasmid (pB-Actin-RL) vector as a control to normalize for transfection efficiency, Figure 3A shows that the luciferase activity driven by the c-KIT promoter was activated by AP-2A in A375SM cells in a dosedependent manner. A 9.5-fold stimulation was observed in cells co-transfected with 6 μg of the plasmid expressing the AP-2A protein, which was not detected in transfections with the parent vector. Conversely, when the pKLuc construct was co-transfected into Mel-501 cells (which express high levels of c-KIT) and increasing concentrations of AP-2B, the dominant-negative form of AP-2 (Buettner et al., 1993) , the luciferase activity was inhibited in these cells ( Figure 3B ). A 48% decrease in luciferase activity was observed with 3.5 μg of the plasmid encoding AP-2B. No further decrease in activity was observed with higher concentrations of AP-2B. It has been shown that AP-2A and AP-2B do not interact directly. The lack of further repression of the c-KIT promoter in Mel-501 cells by AP-2B might be due to the limited amount of a putative adopter protein required for interaction between AP-2A and AP-2B (Buettner et al., 1993) . However, we cannot rule out the possibility that AP-2 is not the sole factor regulating c-KIT expression in these cells. These experiments indicate the presence of functional AP-2 elements within the c-KIT promoter that regulate c-KIT expression in human melanoma cell lines.
To provide direct evidence that the AP-2 sites within the 185 bp proximal c-KIT promoter actually contribute to its activity, we performed site-directed mutagenesis of the AP-2 sites located between -80 to -89 and -139 to -148 upstream of the c-KIT transcription initiation site ( Figure 3C ). Disruption of the upstream AP-2 site located between -139 and -148 significantly inhibited reporter activity in c-KIT-positive Mel-501 cells ( Figure 3E ) and in c-KIT-negative A375SM cells co-transfected with 2 μg of expression vector for AP-2A ( Figure 3D ). Mutations of the downstream AP-2 binding site (-80 to -89) did not alter the luciferase activity in these cells, indicating that the AP-2 site located between -139 and -148 is crucial for the c-KIT promoter activation. This could be explained by the difference in the sequence of these two AP-2 sites in which the site located between -139 to -148 has more homology with the core AP-2 recognition sequence (Williams et al., 1988) . 
Direct interaction of AP-2 with the c-KIT promoter
To determine if AP-2 transactivation of the c-KIT promoter was due to direct AP-2 binding to the c-KIT promoter, we tested a 108 bp fragment from the c-KIT promoter (-68 to -175 , that contains two AP-2 binding sites) for reaction with recombinant human AP-2 (r-h-AP-2) on EMSA gel. Figure 4 shows that r-h-AP-2 bound directly to this fragment. This binding was abrogated by an excess of unlabeled double-stranded AP-2-binding DNA sequences, but not by the AP-1-binding DNA motif. Furthermore, the observed DNA-protein complex was super-shifted by anti-AP-2 antibody but not by anti-CREB antibody (Figure 4 ). In repeated EMSA gel experiments,
we were able to demonstrate that the shifted bands were eliminated by an excess of unlabeled DNA fragments corresponding to the c-KIT promoter region that was used as a probe ( Figure 5A ). To further determine the specificity of the AP-2 reaction with the c-KIT promoter, formation of these complexes was competed out again with an excess of unlabeled oligonucleotides corresponding to the AP-2 consensus binding motif ( Figure 5B , lanes 2-4) but not with an excess of cold double-stranded oligonucleotides that were designed to harbor mutations that disrupt AP-2 binding ( Figure 5B, lanes 6-8) . Collectively, these data show that AP-2 bound directly to a region of the c-KIT promoter required for its transcription. Figure 4 . This binding could be competed out by an excess of unlabeled doublestranded DNA fragments corresponding to the c-KIT promoter region (A), or by oligonucleotides corresponding to the AP-2 consensus binding motif (B) (lanes 2-4), but not by an excess of oligonucleotides with mutations that disrupt AP-2 binding (B) (lanes 6-8).
Ectopic expression of AP-2 in A375SM human melanoma cells
To assess the contribution of the AP-2 transcription factor to c-KIT expression and to the acquisition of the metastatic phenotype in human melanoma cells, we decided to reexpress AP-2 in A375SM cells. A375SM cells are highly metastatic in nude mice (Gutman et al., 1994; Luca et al., 1995; Xie et al., 1997) and also c-KIT negative, and they express low or negligible levels of endogenous AP-2 ( Figure 6A (wild-type) cDNA or an empty vector, neo-resistant colonies were pooled and established in culture. Two independent transfections were performed. Therefore, two transfectants were obtained and designated A375SM-AP2.T1 and A375SM-AP2.T2, respectively. Northern blot analysis using AP-2 cDNA as a probe detected high levels of AP-2 mRNA transcripts in the two transfectants ( Figure 6A ), but only residual levels in parental A375SM or control neo-transfected cells. Expression of AP-2 in the transfected cells was also verified by Western blot analysis using nuclear extracts and anti-AP-2 antibody ( Figure 6B ). The 52 kDa protein was observed in the two transfectants as compared with faint bands in the two neotransfected clones.
To determine whether the AP-2 in the transfected cells is functional, we next analyzed the ability of nuclear extracts from the transfected cells to bind to a consensus AP-2-binding DNA oligonucleotide on an EMSA gel. We used the SB-2 cells as a positive control for cells expressing the AP-2 transcription factor. As shown in Figure 7 , three shifted bands were observed with nuclear extracts from SB-2 cells (lane 2), with the upper band (band 1) being super-shifted when reacted with anti-AP-2 antibody (lane 4) but not with anti-CREB antibody (lane 3). In contrast, nuclear extracts from parental A375SM cells yielded a strong band 2 and very faint bands 1 and 3 ( Figure 7 , lane 5), while nuclear extracts from the two AP-2 transfectants T1 and T2 yielded three strongly shifted bands similar to the pattern observed with nuclear extracts from the SB-2 cells (Figure 7, lanes 6 and 7) . The upper bands (band 1) in the two transfectants were super-shifted 9) . In addition, bands 1 and 3 were competed out by an excess of unlabeled double-stranded oligonucleotide probe, while band 2 was slightly affected.
when reacted with anti-AP-2 antibody (Figure 7 , lanes 8 and 9), and bands 1 and 3 were competed out using excess unlabeled double-stranded oligonucleotide probe (Figure 7 , lanes 10 and 11). Band 2 was slightly competed out with ϫ100 molar excess of unlabeled AP-2 (Figure 7 , lane 11).
To further confirm that the AP-2 in the transfected cells is transcriptionally active, we took advantage of the observation that AP-2 transactivates the metallothionein promoter (Bauer et al., 1994) . To that end, we constructed a luciferase reporter gene expression vector driven by three AP-2 consensus response elements from the human metallothionein gene IIA ligated in front of a minimal TK promoter ( Figure 8A ). The reporter constructs were transfected into control or AP-2-transfected A375SM cells, together with the pB-actin-RL plasmid that served as an internal control for transfection efficiency. Luciferase activity was 5-to 8-fold higher in the AP-2 transfectants A375SM-AP-2.T1 and A375SM-AP-2.T2, respectively, as compared with the neo-control cells ( Figure 8B ). These data demonstrate that the two AP-2 stably transfected T1 and T2 clones expressed high levels of active AP-2.
Upregulation of c-KIT gene expression in AP-2 stably transfected human melanoma cells
Our promoter analyses ( Figure 3A ) indicated that the AP-2 transcription factor is an important regulator of 4363 c-KIT gene expression. We therefore examined the effect of AP-2 re-expression in A375SM cells on c-KIT gene expression. To that end, the expression of the 145 kDa c-KIT receptor was analyzed in the two AP-2 transfectants, T1 and T2. To determine c-KIT protein expression, wholecell lysates were prepared and reacted with specific polyclonal anti-c-KIT antibody, the immunocomplexes were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and c-KIT expression was determined by Western blot analysis. Figure 9 shows that c-KIT was expressed in the two AP-2 transfectants A375SM-AP-2.T1 and A375SM-AP-2.T2 but not in parental or control neo-transfected cells. We used the 
Tumorigenicity and metastatic potential of AP-2 transfected human melanoma cells
We have previously demonstrated that enforced c-KIT expression significantly inhibited tumor growth and metastasis of A375SM human melanoma cells (Huang et al., 1996) . To determine the tumorigenicity of the AP-2-transfected A375SM cells which exhibited increased expression of c-KIT, we injected 1ϫ10 6 cells s.c. into BALB/c nude mice and tumor growth was monitored once a week for 60 days. Both A375SM parental and neotransfected control cells grew in all mice (100% tumor uptake) and reached 1.0-1.4 cm in mean diameter within 6 weeks ( Figure 10 ). In contrast, A375SM AP-2-transfected cells did not begin to form palpable tumors until 3 weeks (T2) or 7 weeks (T1) after injection, and produced smaller tumors (0-4.5 mm in mean diameter). Growth of the A375SM-AP-2.T1 cells differed significantly from parental and neo-control cells at all times (p Ͻ0.01), while the difference between the A375SM-AP.2T2 and parental or neo-transfected cells was statistically significant 5 and 6 weeks after injection (p Ͻ0.05) (Figure 10 ). These data suggest that transfection of AP-2 into A375SM cells suppressed their tumor growth in vivo.
In the next set of experiments, the metastatic potential of AP-2-transfected A375SM cells was determined in an experimental lung metastasis assay Xie et al., 1997b) . To that end, BALB/c nude mice were injected i.v. with 1ϫ10 6 A375SM AP-2-transfected, parental, or neo-control cells, and 60 days later the number of lung metastases was counted. As shown in Table I , A375SM and A375SM-Neo (Neo.a and Neo.b, respectively) produced a high number of lung tumor colonies in all injected mice. In contrast, the A375SM-AP-2-transfected cells did not metastasize to the lungs (T1) or produced a few lung metastases in some mice (T2).
To determine whether those metastatic revertants still overexpressed AP-2, five metastatic nodules were isolated and established as individual cell lines. AP-2 expression in these cell lines was analyzed by Northern blot. We could not detect increased levels of AP-2 mRNA in these cell lines as compared with parental and neo-control cells (data not shown). These data implied that the occasional gain of metastatic potential in A375SM-AP-2 cells was due to the loss of exogenous AP-2 expression. Alternatively, the pooled transfectant cells may contain some neoresistant but AP-2-negative cells. In this case, the AP-2-negative nodes could represent a selection of these cells rather than 'revertants'. To determine whether the inhibition of tumor growth and the decreased capacity to produce lung metastases by A375SM-AP2 cells in vivo was due to different growth rates in vitro, we compared their doubling time with control cells in cultures. When the cells were cultured in medium containing 0.5% fetal bovine serum (FBS) (a limiting condition), the cell doubling times of A375SM parental and neo-control cells were indistinguishable from the A375SM-AP-2 cells (45 h). In contrast, in medium containing 10% FBS, the doubling time for parental and neo-transfected cells was 24 h while the AP-2-transfected cells doubled every 36 h. In addition, in medium containing 10% FBS, the AP-2-transfected cells exhibited morphological changes: they were enlarged and flat, and had an increased number of multinucleated cells (data not shown). These later effects could be due to the presence of SCF in the serum (see below).
Induction of apoptosis in AP-2-transfected melanoma cells by SCF
Previous studies from our laboratory have demonstrated that SCF induces apoptosis in c-KIT-expressing human melanoma cells under both in vitro and in vivo conditions (Huang et al., 1996) . Therefore, we next determined whether expression of c-KIT in AP-2-transfected A375SM cells is associated with apoptosis. A375SM-AP2.T2 and A375SM-neo cells were treated with 150 ng/ml human recombinant SCF in 0.5% FBS-containing medium for 72 and 96 h. Apoptosis was determined by terminal deoxynucleotidyl transferase-mediated nick end-labeling (TUNEL) staining of DNA fragmentation. The frequency of apoptosis in A375SM-AP2.T2 cells after 72 h was 17 Ϯ 3% versus 3 Ϯ 0.4% for neo-control A375SM cells in medium with SCF (mean Ϯ SEM, p Ͻ0.01). After 96 h, SCF induced apoptosis of 27 Ϯ 4% in A375SM-AP2.T2 cells as compared with 4 Ϯ 1% in control cells. The frequency of apoptosis in A375SM-AP2.T2 cells was 5 Ϯ 0.5% versus 2 Ϯ 0.4% for neo-control cells in medium lacking SCF (mean Ϯ SEM, p Ͻ0.05). These results demonstrate that SCF treatment resulted in marked induction of apoptosis in AP-2-transfected A375SM cells, which can be explained by transactivation of c-KIT gene expression by the AP-2 transcription factor. As apoptosis of melanoma cells expressing c-KIT also occurs in vivo due to the secretion of SCF by the host (Huang et al., 1996) , this is a potential mechanism by which transfection of melanoma cells with the AP-2 transcription factor leads to inhibition of tumor growth and metastasis.
Discussion
In this paper we demonstrate for the first time that the transcription factor AP-2 plays a major role in regulating tumor growth and metastasis of human melanoma. Loss of AP-2 results in downregulation of c-KIT, enhancement of melanoma tumorigenicity and metastasis, and failure of SCF to induce apoptosis.
c-KIT is a tyrosine-kinase type receptor whose expression progressively decreases during local tumor growth and invasion of human melanomas (Lassam and Bickford, 1992; Natali et al., 1992; Zakut et al., 1993) . Lack of c-KIT expression directly correlates with the metastatic potential of human melanoma cells in nude mice (Gutman et al., 1994) . Ectopic expression of c-KIT in highly metastatic cells inhibited their tumor growth and metastatic potential in vivo. In addition, we found that exposure of c-KIT-positive melanoma cells to SCF, the ligand for c-KIT, under both in vitro and in vivo conditions, triggered apoptosis of these cells but not of normal melanocytes (Huang et al., 1996) , thus providing a mechanism by which suppression of c-KIT expression could contribute to the metastatic phenotype of human melanoma. The mechanism by which malignant melanoma cells lose c-KIT expression was unclear. Here we provide evidence for the first time that in metastatic melanoma cells, lack of c-KIT expression correlates with lack of expression of the AP-2 transcription factor, and that in melanoma cells AP-2 serves as a positive regulator of c-KIT expression. Indeed, re-expression of AP-2 in the highly metastatic A375SM cells resulted in re-expression of the c-KIT receptor and in turn inhibition of tumor growth and metastasis.
Upregulation of c-KIT expression in the AP-2-transfected cells might be one of the mechanisms (via apoptosis) for the reduction in tumorigenicity and the ability of these cells to form lung metastases in vivo. However, in other studies we have demonstrated that the adhesion molecule MCAM/MUC18 that plays a major role in the acquisition of the metastatic phenotype in human melanoma (Lehmann et al., 1989; Luca et al., 1993; Xie et al., 1997a) is also regulated by the AP-2 transcription factor (Jean et al., 1998) . In these studies we showed that loss of AP-2 resulted in upregulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melan-oma cells. The MCAM/MUC18 promoter contains four AP-2 binding sites and its activation is regulated by AP-2, thus representing a second example of 'melanoma antigen' to be regulated by AP-2 (Jean et al., 1998) . In addition, other genes that are involved in the progression of human melanoma such as MMP-2, the metalloproteinase that degrades collagen type IV (Luca et al., 1997) , E-cadherin (Cowley and Smith, 1996) , p21/WAF-1 (Jiang et al., 1995; Vidal et al., 1995) , HER-2 (Natali et al., 1994) and bcl-2 (Van den Oord et al., 1994; Grover and Wilson, 1996) have either already been shown to be regulated by AP-2 (Bosher et al., 1995; Zeng et al., 1997) or represent likely targets for AP-2 gene regulation based on the existence of AP-2 elements in their promoters. Therefore, we propose that loss of AP-2 expression may be the crucial event in the development of malignant melanoma.
The mechanisms accounting for lack of expression of AP-2 or downregulation in malignant melanoma cells are currently unknown. One tempting possibility is to link the lack of AP-2 expression to cytogenetic evidence demonstrating that the majority of malignant melanoma cells exhibit deletion of the distal portion of the long arm of chromosome 6 (Pathak et al., 1983; Trent et al., 1983; Copeman, 1992; Healy et al., 1995; Zhang et al., 1995) or more importantly with abnormalities in the short arm of chromosome 6 (6p), near the HLA locus to which the AP-2 gene is mapped (Gaynor et al., 1991) . Indeed, deletions and loss of heterozygosity (LOH) have been reported in this region in malignant melanoma (Pathak et al., 1983; Walker et al., 1995) . Moreover, re-introduction of chromosome 6 into metastatic melanoma cells inhibited their tumorigenicity and metastatic potential (Trent et al., 1990; Welch et al., 1994) . These studies suggest that inactivation of a tumor suppressor gene on chromosome 6 may be the critical event in the progression of melanoma. The mechanism for the lack of AP-2 expression in the metastatic melanoma cells used in our study is currently under investigation.
Epidemiological data suggest that exposure to UV radiation plays a major role in the development of at least some cutaneous melanoma (Halman et al., 1980; Romerdhal et al., 1988) . The role of UV radiation in the development of human cutaneous melanoma to its metastatic state is not very well characterized. We have recently demonstrated that UV-B irradiation can promote tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin-8 (Singh et al., 1995; Luca et al., 1997) . A provocative idea will be to link abnormalities in the AP-2 gene with UV radiation that serves as a carcinogen for cutaneous melanoma. Indeed, two recent reports have shown that both UV-A and UV-B radiation can alter the expression and activity of the AP-2 transcription factor in human keratinocytes and epidermoid carcinoma cell line (A431) (Ariizumi et al., 1996; Grether-Beck et al., 1996) . The question of whether UV radiation can effect AP-2 expression and activity in human primary cutaneous melanoma is currently under investigation in our laboratory.
Despite improvement in early detection and treatment of primary melanoma, the diagnosis of melanoma is often made after the cancer has already metastasized to the regional and distant lymph nodes, liver, lung and central nervous system (Fidler, 1992) . Since current staging systems enable us to identify only some of the melanoma patients who will develop metastases, better prognostic determinants need to be identified. Clearly, AP-2 falls within this category. Our analysis of AP-2 expression in human melanoma cell lines (although limited to a small number of melanoma cell lines tested) indicates that AP-2 expression was observed only in cell lines derived from primary cutaneous melanoma (radial growth phase) such as SB-2 and Mel-501 (both cell lines are low-tumorigenic and non-metastatic in nude mice), but not in cell lines derived from metastatic lesions. It will be extremely important to determine at what stage in the transformation process from melanocytes to malignant melanoma this event occurs. Currently, several hundred human melanoma specimens gathered at the M.D.Anderson Cancer Center representing different stages in the progression of human melanoma (from atypical nevi to metastatic lesions) are being evaluated for AP-2 expression. Our aim is to establish the validity of using the AP-2 protein as a prognostic marker and eventually as a common target for anti-tumor and antimetastatic therapy.
Materials and methods

Cell lines and culture conditions
The A375-P human melanoma cell-line was established in culture from a lymph node metastasis of a melanoma patient (Kozlowski et al., 1984) . The highly metastatic derivative A375SM was established from pooled lung metastases produced by the A375-P cells injected i.v. into nude mice (Li et al., 1989) . The SB-2 cell line was isolated from a primary cutaneous lesion and was a gift of Dr B.Giovanella (St Joseph's Hospital Cancer Center, Research Laboratory, Houston, TX). In nude mice, SB-2 cells are poorly tumorigenic and nonmetastatic (Luca et al., 1993; Singh et al., 1995) . SB-3 was isolated from a cutaneous metastasis and was found to be with non to low metastatic potential in nude mice (Luca et al., 1995) . The human melanoma cell line WM-2664 was purchased from ATCC, and is highly metastatic in nude mice (Luca et al., 1995) . Mel-501 and Mel-888 cell lines were provided by Dr Ruth Halaban (Yale University School of Medicine, New Haven, CT). In nude mice, Mel-501 and Mel-888 are low metastatic. The MeWo cell line was kindly provided to us by Dr Z.Ronai (Mount Sinai, NY). In nude mice MeWo cells have low to intermediate metastatic potential.
The melanoma cell lines were maintained in culture as adherent monolayers in Eagle's minimal essential medium (MEM) supplemented with 10% FBS, sodium pyruvate, nonessential amino acids, L-glutamine, two-fold vitamin solution and penicillin-streptomycin (Flow Laboratories, Rockville, MD), and incubated in 5% CO 2 , 95% air at 37°C.
Animals
Male athymic BALB/c nude mice were purchased from the Animal Production Area of the National Cancer Institute, Frederick Cancer Research Facility (Frederick, MD). The mice were housed in laminar flow cabinets under specific pathogen-free conditions and used at 8 weeks of age. Animals were maintained in facilities approved by the American Association for Accreditation of Laboratory Animal Care and in accordance with current regulations and standards of the United States Department of Agriculture, Department of Health and Human Services, and National Institutes of Health.
Plasmid constructs
The c-KIT promoter luciferase plasmid (pKluc) was generated by PCR amplification of the 5Ј-flanking region of the c-KIT gene (-1 to -1215 nucleotides). The adenosine in the ATG codon was designated ϩ1. Nucleotides upstream from this site were assigned negative numbers. The PCR product was subcloned upstream of the firefly luciferase gene by using HindIII and KpnI sites. The sequence of the promoter upstream of the luciferase reporter was verified. The pB-Actin-RL was generated by digestion of pBluescript B-Actin plasmid (kindly provided by Dr Bing Su at M.D.Anderson Cancer Center) with XhoI-HindIII, and subcloning the β-actin promoter upstream of the Renilla luciferase reporter gene by ligation into XhoI-HindIII-digested pRL-null (Promega Corp., Madison, WI). The AP-2 binding site luciferase reporter (3XAP-2-Luciferase) was generated by digestion of 3XAP2 CAT-reporter plasmid (Buettner et al., 1993; Kannan et al., 1994) with HindIII and KpnI sites. The sequence of the promoter upstream of the luciferase reporter was verified. The AP-2 expression plasmids pSG5-AP-2 and pSG5-Neo-AP-2, their control vectors pSG5 and pSG5-Neo, and the AP-2B expression plasmid pSG-5-Neo-AP-2B were described previously (Kannan et al., 1994) .
Mutagenesis
The mutants Mut.1-pKluc and Mut.2-pKluc were generated from the pKluc vector using the QuickChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). The following oligonucleotides were used as primers: 5Ј-GCGAGGAGGGGTTTGGTTGCGCGCAGAGGGAGG-3Ј and 5Ј-CCTCCCTCTGCGCGCAAGCCAAACCCCTCCTCGC-3Ј for the mutant Mut.1-pKluc, and 5Ј-CGCCGCTCGCGGTTCTGGTTGCT-CGGCTTTGC-3Ј and 5Ј-GCAAAGCCGAGCAACCAGAACCGCG-AGCGGCG-3Ј for the mutant Mut.2-pKluc. The presence of mutations were verified by sequencing with the primer 5Ј-CGGCATTAAC-ACGTC-3Ј.
Transient transfections and luciferase assays
Melanoma cells (2ϫ10 5 ) were transfected by using the Lipofectin reagent (Life Technologies, Inc., Gaithersburg, MD). For the experiments shown in Figure 1 , 2 μg of pKluc and 0.05 μg pB-Actin-RL-plasmids were used. For the experiments shown in Figure 3A , 2 μg of pKluc, 0.05 μg of pB-Actin RL plasmid, and 1-5 μg of pSG5-AP-2 expression plasmids were used. For the experiments shown in Figure 3B , 1 μg of pKluc and 0.05 μg of pB-Actin-RL plasmids were used. At 10 h post-transfection, the medium was changed to serum-containing complete medium and the cells were incubated further for 48 h at 37°C. The cells were then washed with phosphate-buffered saline (PBS) and harvested in Passive Lysis Buffer (Promega Corp., Madison, WI). Quantitation of firefly and Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega Corp., Madison, WI). Normalization of transfection efficiency was done using a co-transfected β-actin-Renilla luciferase expression vector. Fold activation or inhibition of luciferase activity was calculated relative to control cells which were given the reference value of 1 as described by Janknecht and Hunter (1997) .
Stable transfection of melanoma cells with AP-2 5ϫ10 6 A375SM cells were transfected using 15 μl of lipofectin reagent (Life Technologies, Inc. Gaithersburg, MD) and 2 μg of pSG5-Neo-AP-2 expression vector or control pSG5-Neo vector. Transfections were carried out according to the manufacturer's instructions. At 10 h posttransfection, the medium was changed to serum-containing complete medium and the cells were further incubated for 48 h at 37°C. Cells were selected after 48 h with standard medium containing G418 500 μg/ml. Fourteen days later, neo-resistant colonies were isolated by trypsinization and established in culture.
Northern blot analysis mRNA was extracted from 10 6 -10 7 cultured cells using the FastTrack TM KIT (Invitrogen Co., San Diego, CA). For Northern blot analysis, 2.5 μg of purified mRNA was separated on 1% denaturing formaldehyde/ agarose gels, electrotransferred at 0.6 A to GeneScreen ® nylon membrane (DuPont Co., Boston, MA) and UV cross-linked with 120 000 μJ/cm 2 using a UV Stratalinker 1800 (Stratagene, La Jolla, CA). Hybridizations were performed as previously described (Luca et al., 1993 (Luca et al., , 1995 and filters were washed three times with 30 mM NaCl/3 mM sodium citrate pH 7.2/sodium dodecyl sulfate (0.1% w/v at 60°C).
The DNA probes used in these analyses were a 1.2 kb SaII fragment of the c-KIT gene (phc-KIT-171, American Type Culture Collection; Yarden et al., 1987) , a 1.9 kb AP-2 cDNA fragment digested with EcoRI from the pNAP2 plasmid (Kannan et al., 1994) , and a 1.3 kb PstI cDNA fragment corresponding to rat glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Fort et al., 1985) . Each DNA fragment was purified by agarose gel electrophoresis, recovered using Gene Clean (BIO 101, La Jolla, CA), and radiolabeled by the random primer technique using [α-32 P]deoxyribonucleotide triphosphates.
Western blot
Melanoma cell nuclei were isolated as described previously (Hudson et al., 1995) . Isolated nuclei were lysed by using Triton X-100 lysis buffer [150 mm NaCl, 25 mM Tris pH 7.5, 1% (w/v) Triton X-100, 2 mM EDTA, 1 mM PMSF, 10 μg/ml trypsin inhibitor, 20 mM leupeptin, 0.15 U/ml aprotinin] on ice for 20 min. The soluble protein in the lysates was then separated by centrifugation at 14 000 r.p.m. for 20 min at 4°C. Protein concentration was assayed by the Bio-Rad protein assay reagent (Bio-Rad Laboratories) and stored at -70°C. Before loading, protein samples were boiled in sample buffer [62.5 mM Tris-HCl pH 6.8, 10% (w/v) glycerol, 100 mM DTT, 2.3% SDS, 0.002% bromophenol blue] for 2-5 min and cooled on ice for 5-10 min. Samples (30 μl) were loaded and separated on 10% SDS-PAGE at 150-200 V for 45-60 min in electrophoresis buffer (25 mM Tris-HCl pH 8.3, 192 mM glycine, 0.1% SDS). Proteins in the gels were electrophoretically transferred onto immobilon-P transfer membrane (Millipore) in 1ϫ transfer buffer (25 mM Tris-HCl, 192 mM glycine, 20% methanol) at 100 V for 1 h at 4°C. The membranes were washed in blocking buffer [TBS (10 mM TrisHCl pH 8.0, 150 mM NaCl) and 3% BSA, 1% OVA, 0.02% NaN 3 ] for 2 h at room temperature (RT) with shaking, and then rinsed once briefly with TTBS (99.9% TBS, 0.1% Tween 20). The membrane was incubated in diluted 1:500 anti-AP-2 polyclonal antibody (C-18, Santa Cruz Biotechnology) overnight at 4°C. The membranes were rinsed twice briefly with TTBS and washed three times with TBS at RT, and then incubated with a dilution of 1:5000 second antibody (anti-rabbit immunoglobulin, horseradish peroxidase-linked F(ab)2 fragment from donkey) for 1 h at RT with shaking. The membranes were rinsed twice briefly and washed three times with TBS at RT with shaking. The probe proteins were detected with Amersham ECL system according to the manufacturer's instructions.
Electrophoretic mobility gel shift assay (EMSA)
The double-stranded DNA fragment corresponding to c-KIT promoter region of -68 to -175 was amplified by PCR. c-KIT promoter luciferase reporter plasmid served as the template. The volume was adjusted to 50 μl by adding 200 ng of DNA, 35 μl of PCR buffer (10ϫ concentrated; 500 mM KCl, 100 mM Tris, pH 8.3), 2 μl of 25 mM MgCl 2 , 0.5 μl each two primers (15 μM), 1 μl each of dATP, dCTP, dGTP, and dTTP, (2.5 mM), and 0.5 U of Taq DNA polymerase. The PCR amplification was carried out for 30 cycles in a DNA thermal cycler (Perkin-Elmer/ Cetus). Each cycle included denaturation at 94°C for 1 min, re-annealing of primers at 55°C for 1 min and extension at 72°C for 1.5 min. The sequence structures of the primers are: c-KIT primer F 5Ј-GGCGCG-AGGGAGGGGAGGCGAGGA-3Ј and c-KIT primer R 5Ј-AAGTGCA-GCGAGCGCGGCAAAGCC-5Ј. The 108 bp PCR product was fractionated on electrophoresed agarose gel and isolated by using Gene Clean kit (Bio 101) and used in EMSA. Nuclear protein extracts were assayed for protein content by the Bio-Rad protein assay reagent (Bio-Rad Laboratories) and stored at -70°C. Gel shift assays were performed based on the method of Carthew et al. (1985) . DNA reactions were performed in a volume of 25 μl with 1 μg of poly(dI-dC), 2 μg BSA, and 12% glycerol in HEPES buffer (pH 7.9). Ten micrograms of nuclear extracts and 30 000 c.p.m. of end-labeled double-stranded DNA probe were added to the reaction mixture. The binding reactions were left on ice for 30 min. Protein-DNA complexes were resolved on a 6% non-denaturating polyacrylamide gel. The gels were dried and exposed to X-ray film at -80°C overnight. Human recombinant AP-2 protein was purchased from Promega. For competition assays, unlabeled olignucleotides were added 10 min before adding the labeled probes. Wild-type or mutant AP-2 oligonucleotides were purchased from Santa-Cruz. The wild-type AP-2 binding motif 5Ј-GAT CGA ACT GAC CGC CCG CGG CCC CT-3Ј was used as a probe in the EMSA gels. In the mutated AP-2 oligonucleotides, the underlined CC were changed to TT. Anti-AP-2 antibodies (Santa-Cruz, CA) were used in the supershift analyses.
Immunoprecipitation
Melanoma cells (1.5-2.5ϫ10 6 in 10 ml of MEM) before and after transfection were seeded in 100 mm Petri dishes and incubated overnight. The cells were scraped off and washed in 4°C PBS containing 5 mM EDTA. The cell pellets were lysed into 100 μl Triton X-100 lysis buffer and kept on ice for 20 min. The soluble protein in the lysates was then separated by centrifugation at 14 000 r.p.m. for 20 min at 4°C, and aliquoted and stored at -70°C until use. Protein concentration in the lysates was determined by the Bio-Rad protein assay reagent (Bio-Rad Laboratories). The A375SM cell lysates were adjusted to the same volume (1 ml) and same protein concentration (2.5 mg) by using Triton lysis buffer. Mel-888 cell lysate was adjusted to 1 ml volume and 30 μg protein by lysis buffer as above. Cell lysates were incubated with 25 μl human anti-c-KIT polyclonal antibody (kindly provided by Dr Keith Langley, Amgen, Thousand Oaks, CA) for 4 h at 4°C and then added 50 μl of protein A-agarose for overnight incubation with rotation. The 4367 pellets were washed three times and boiled with sample buffer. The supernatants were loaded onto and separated on 7.5% SDS-PAGE. The Western blot analysis was performed as described above by using the same anti-c-KIT antibody.
Tumor cell injections
To prepare tumor cells for inoculation, cells in exponential growth phase were harvested by brief exposure to 0.25% trypsin ϩ 0.2% EDTA solution (w/v). The flask was sharply tapped to dislodge the cells, and supplemented medium was added. The cell suspension was pipetted to produce a single-cell suspension. The cells were washed and resuspended in Ca 2ϩ -and Mg 2ϩ -free HBSS to the desired cell concentration. Cell viability was determined by Trypan-Blue exclusion, and only single-cell suspensions of 90% viability were used. Tumors (s.c.) were produced by injecting 1ϫ10 6 tumor cells in 0.2 ml HBSS over the right scapular region. Growth of s.c. tumors was monitored by examination of the mice every day and weekly measurement of tumors with calipers. The mice were killed 2 months after injection, and tumors were processed for hematoxylin and eosin staining.
For experimental lung metastasis 1ϫ10 6 tumor cells in 0.2 ml of HBSS were injected into the lateral tail vein of nude mice. The mice were killed after 60 days, and the lungs were removed, washed in water, and fixed with Bouin's solution for 24 h to facilitate counting of tumor nodules as described previously Huang et al., 1996) . The number of surface tumor nodules was counted under a dissecting microscope. Sections of the lungs were stained with hemotoxylin and eosin to confirm that the nodules were melanoma and to identify micrometastasis.
Terminal deoxynucleotidyl transferase-mediated nick endlabeling method for in situ detection of apoptotic cells
The TUNEL method (Gavrieli et al., 1992) was used to identify DNA fragmentation in cells undergoing apoptosis as previously described . Briefly, nuclei on slides with cell cultures were stripped from proteins by incubation with 20 μg/ml proteinase K for 15 min at RT, and the slides were then washed four times in double-distilled water (ddH 2 O) for 2 min. Endogenous peroxidase was inactivated by covering the sections with 2% H 2 O 2 for 5 min at RT. The sections were rinsed with DDW and immersed in TDT buffer (30 mM Tris-HCl pH 7.2, 140 mM sodium cacodylate, 1 mM cobalt chloride). TDT (0.3 μ/μl) and biotinylated dUTP in TDT buffer were then added to cover the sections and then incubated in a humidified atmosphere at 37°C for 60 min. The sections was terminated by transferring the slides to TB buffer (300 mM sodium chloride, 30 mM sodium citrate) for 15 min at RT. The sections were rinsed with ddH 2 O, covered with 2% aqueous solution of BSA for 10 min at RET, rinsed in ddH 2 O, and immersed in PBS for 5 min. The sections were covered with extraavidin peroxidase (BioMakor, Rehovot, Israel), diluted 1:10-20 in water, incubated for 30 min at 37°C, washed in ddH 2 O, immersed for 5 min in PBS and stained with AEC for~30 min at 37°C.
Statistics
The significance of the in vitro results was determined by the Student's t-test (two-tailed); the significance of the in vivo metastasis results was determined by the Mann-Whitney U-test.
